Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Azithromycin Clear all
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Study to Determine the Effect of Azasite on Corneal Surface Irregularity

NCT01797107
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
Azasite
Drug
Lead sponsor
Philadelphia Eye Associates
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 17, 2026, 1:38 PM EDT
Withdrawn Phase 1 Interventional

A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease

NCT02630394
View directory record Official record
Conditions
Sickle Cell Disease, Acute Chest Syndrome
Interventions
Azithromycin
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
6 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Jackson, Mississippi • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 17, 2026, 1:38 PM EDT
Completed No phase listed Observational Results available

Comparative Effectiveness of Antibiotics for Respiratory Infections

NCT02297815
View directory record Official record
Conditions
Acute Otitis Media, Acute Sinusitis, Group A Streptococcal Pharyngitis
Interventions
Broad-spectrum antibiotics, Narrow-spectrum antibiotics
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 12 Years
Enrollment
2,472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Oct 17, 2026, 1:38 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Infant Mortality Reduction by the Mass Administration of Azithromycin

NCT04716712
View directory record Official record
Conditions
Child Mortality
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Month to 11 Months
Enrollment
694,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 17, 2026, 1:38 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term

NCT03801252
View directory record Official record
Conditions
Obesity, Induction of Labor Affected Fetus / Newborn
Interventions
Cefazolin, Placebo, Azithromycin
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 17, 2026, 1:38 PM EDT
Recruiting Phase 3 Interventional

Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children

NCT05026749
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
AZM Group, Control Group
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
3 Days to 2 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 17, 2026, 1:38 PM EDT
Completed Not applicable Interventional

An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)

NCT00002090
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Boston, Massachusetts • Syracuse, New York • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV

NCT03431168
View directory record Official record
Conditions
HIV, Pregnancy Malaria, Sexually Transmitted Infection
Interventions
Azithromycin/TMPS, Placebo/TMPS
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
16 Years to 55 Years · Female only
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Oct 17, 2026, 1:38 PM EDT
Terminated Phase 2 Interventional Results available

Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19

NCT04358068
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
Hydroxychloroquine (HCQ), Azithromycin (Azithro), Placebo for Hydroxychloroquine, Placebo for Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
11
States / cities
Birmingham, Alabama • San Diego, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 17, 2026, 1:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vanderbilt Pertussis Exposure Study: PEP in Vaccinated Healthcare Workers Following Pertussis Exposure

NCT00469274
View directory record Official record
Conditions
Pertussis
Interventions
Antibiotic PEP
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 64 Years
Enrollment
1,102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Oct 17, 2026, 1:38 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis

NCT01408082
View directory record Official record
Conditions
Blepharitis
Interventions
ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined), Azasite, Dexamethasone, Vehicle
Drug · Other
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
917 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
45
States / cities
Chandler, Arizona • Phoenix, Arizona • Glendale, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 17, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)

NCT00105534
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
AzaSite, Vehicle
Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
12 Months and older
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
32
States / cities
Flagstaff, Arizona • Cudahy, California • Petaluma and Santa Rosa, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Oct 17, 2026, 1:38 PM EDT
Terminated Phase 2 Interventional Results available

Non-comparative Trial of the Combination of HCQ and AZI in the Treatment of ICU Patients

NCT04458948
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Azithromycin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 17, 2026, 1:38 PM EDT
Withdrawn Phase 2 Interventional

Asymptomatic COVID-19 Trial

NCT04374552
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Hydroxychloroquine sulfate &Azithromycin, Placebo
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
20 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 17, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)

NCT00105469
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
AzaSite, Tobramycin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Year and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
26
States / cities
Birmingham, Alabama • Littleton, Colorado • Atlantis, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 17, 2026, 1:38 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

NCT05654922
View directory record Official record
Conditions
Pre-Bronchiolitis Obliterans Syndrome
Interventions
ARINA-1, Standard of care only
Drug · Other
Lead sponsor
Renovion, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 17, 2026, 1:38 PM EDT
Completed Phase 2 Interventional

A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children

NCT00000811
View directory record Official record
Conditions
Bacterial Infections, Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Azithromycin, Atovaquone, Sulfamethoxazole-Trimethoprim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 18 Months
Enrollment
690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
72
States / cities
Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 17, 2026, 1:38 PM EDT
Not listed Phase 1Phase 2 Interventional

Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19

NCT04344457
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Indomethacin, Zithromax Oral Product
Drug
Lead sponsor
Perseverance Research Center, LLC
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Scottsdale, Arizona • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 17, 2026, 1:38 PM EDT
Withdrawn Phase 3 Interventional

A P3 Comparator Trial in Community Acquired Bacterial Pneumonia

NCT02269644
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
Dalbavancin, Linezolid, Linezolid Placebo, Azithromycin
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Butte, Montana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 17, 2026, 1:38 PM EDT
Completed Phase 4 Interventional

Azithromycin in the Treatment of M. Avium Complex Lung Disease

NCT00599079
View directory record Official record
Conditions
Mycobacterium Avium Complex Lung Disease
Interventions
Azithromycin
Drug
Lead sponsor
The University of Texas Health Science Center at Tyler
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2017
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 17, 2026, 1:38 PM EDT
Terminated Phase 2 Interventional Results available

PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients

NCT01919996
View directory record Official record
Conditions
Pharyngitis, Tonsillitis
Interventions
Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
Rancho Cordova, California • Chicago, Illinois • Murray, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2016 · Synced Oct 17, 2026, 1:38 PM EDT
Completed Phase 4 Interventional Results available

Individualizing Treatment for Asthma in Primary Care

NCT06272370
View directory record Official record
Conditions
Asthma, Bronchial Diseases, Respiratory Tract Infections, Lung Diseases, Obstructive, Lung Diseases, Respiratory Hypersensitivity, Immune System Diseases
Interventions
Asthma Symptom Monitoring online tools, Inhaled Steroids, Azithromycin Pill
Other · Drug
Lead sponsor
DARTNet Institute
Government
Eligibility
12 Years to 75 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 17, 2026, 1:38 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia

NCT02605122
View directory record Official record
Conditions
Community-acquired Bacterial Pneumonia
Interventions
Solithromycin, Standard of Care
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
2 Months to 17 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 17, 2026, 1:38 PM EDT
Completed Phase 2 Interventional

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period

NCT00892970
View directory record Official record
Conditions
Blepharitis
Interventions
Azithromycin ophthalmic solution, 1%, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
33
States / cities
Little Rock, Arkansas • Artesia, California • Azusa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Oct 17, 2026, 1:38 PM EDT